Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00151528 · ClinicalTrials.gov registry record · Phase 3
An Open-Label Trial of Pregabalin in Patients With Fibromyalgia
A Phase 3 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 3
- Development phase
- 428
- Enrollment target
NCT00151528: Completed Phase 3 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
NCT00151528 is a Phase 3 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 428 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (45% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00151528, a Phase 3 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 428 participants
- Enrollment target
Study Summary
The main purpose of this protocol is to evaluate the long-term safety of pregabalin in patients who participated in the previous fibromyalgia Study A0081056 and who wish to receive open-label pregabalin therapy.
Interventions
- DRUG Pregabalin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 428 participants |
| Start Date | 2005-01 |
| Est. Completion | 2006-06 |
| Phase | Phase 3 |
What the finished NCT00151528 record still lists
NCT00151528 is an interventional study that assigns participants to a tested intervention. The registered 428 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (45% lower).
The record links to 0 conditions, and to 1 intervention - of which Pregabalin is the first listed.
NCT00151528 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00151528 about?
NCT00151528 is a clinical study titled "An Open-Label Trial of Pregabalin in Patients With Fibromyalgia". The main purpose of this protocol is to evaluate the long-term safety of pregabalin in patients who participated in the previous fibromyalgia Study A0081056 and who wish to receive open-label pregabalin therapy.
What is the current status of trial NCT00151528?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 428 participants. The study started on 2005-01. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00151528?
The interventions under investigation include: Pregabalin (DRUG).
Who is sponsoring clinical trial NCT00151528?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00151528's enrollment target sits among peer trials
428 878th of 2000 higher than 1,121 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05566431 · 428 participants · NA
Benchmark Evidence Led by Latin America: Trial of Intracranial Pressure - Pediatrics
- NCT05646316 · 428 participants · Phase 3
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
- NCT05797610 · 428 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
- NCT06073626 · 428 participants · NA
Addressing Genomic Disparities in Cancer Survivors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia